Description

Overview

Mechanism: CJC-1295 DAC acts as a GHRH analog, stimulating GH release from somatotroph cells. Study Insights: It has been studied for effects on fat metabolism, lean mass preservation, bone health, and sleep regulation through GH pathways. Key Findings: Its long-acting profile and GH-releasing activity make it a focus of research in metabolic and regenerative contexts.

Chemical Makeup

Molecular Formula: C152H252N44O42

Molecular Weight: 3367.95 g/mol

Other Names: CJC-1295, CJC-1295 with DAC, DAC: GRF, Long-acting GHRH analog

Mechanism of Action

Mechanism: CJC-1295 DAC binds to GHRH receptors on somatotroph cells, activating G-protein–mediated signaling and secondary messengers like cAMP. This leads to phosphorylation of transcription regulators and enhanced GH gene expression. GH then stimulates IGF-1 production in the liver and other tissues via the JAK-STAT pathway. Key Findings: The peptide prolongs GH stimulation while maintaining receptor activity, enabling sustained IGF-1 elevation.

GH Pulsatility & IGF-1 Studies

Mechanism: CJC-1295 DAC boosts GH pulsatility and elevates circulating IGF-1 through sustained stimulation of somatotroph cells. Study Insights: Clinical studies reported clear increases in GH secretion and IGF-1 levels after both single and repeated administrations. Key Findings: Repeated exposure produces prolonged GH and IGF-1 elevation well beyond typical GHRH analog durations.

Animal Studies & Body Composition

Mechanism: In animal models, CJC-1295 DAC stimulates GH production even in GHRH-deficient states. Study Insights: Regular administration preserved lean mass and reduced fat accumulation compared to controls. Key Findings: Research suggests potential impacts on muscle and bone structure while maintaining normal fat levels.

Half-life & Structural Modifications

Mechanism: Four amino acid substitutions at positions 2, 8, 15, and 27 increase enzymatic resistance, while DAC technology extends plasma half-life. Study Insights: These modifications improve bioavailability and peptide stability against degradation. Key Findings: The result is a long-acting GHRH analog with a half-life extended from minutes to several days.

Ancillary Studies

Mechanism: CJC-1295 DAC has been explored for various applications including visceral obesity in HIV models. Study Insights: Some studies were discontinued or exploratory, but regulatory testing has confirmed its classification as a GH-releasing factor. Key Findings: It remains under investigation for diverse metabolic and endocrine research contexts.

Disclaimer

All products offered by America1stPeptides.com are intended strictly for laboratory and scientific research purposes only. These products are not approved by the FDA, are not medicines or supplements, and are not sold for human consumption, medical treatment, or veterinary use. Any discussion of potential benefits is based solely on preclinical findings.